The DOI matches its Crossref record.
Human primary prostate tumor cell line, ALVA‐31: A new model for studying the hormonal regulation of prostate tumor cell growth
Abstract
A new human prostate tumor cell line (ALVA-31) has been established from a biopsy specimen of primary tumor obtained during prostatectomy. The cell line has been maintained for more than 48 months in stable growth. The in vitro doubling time was determined to be approximately 26 hr. The chromosome number ranged from 24-112, with a modal number of 59 tested over several time points throughout continuous culture. Karyotypic analysis of late-passaged cells demonstrated approximately 70 human chromosomes, 8-14 markers, and two X chromosomes without a Y chromosome. Prostatic origin was confirmed by the expression of both prostate specific antigen and prostatic acid phosphatase, using specific antisera and immunoradiolabelling techniques. Prostate tumor xenografts were grown in intact male, castrate male, and female athymic mice; however, the rate of tumor growth was clearly dependent upon serum testosterone levels.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
ALVA-31 was originally established in 1993 as a human prostate carcinoma, but was found to be identical to PC-3 in 2001.
“This cell line was originally established in 1993 as a human prostate carcinoma [35], but was found to be identical to a different human prostate carcinoma, the PC-3 cell line, in 2001 [36, 37].”
From The ghosts of HeLa: How cell line misidentification contaminates the scientific literature (2017) · cites this paper as [35]
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 35
- Reid LM, 1980, Male Accessory Sex Glands, 617
- Williams RD, 1980, Human urologic cancer cell lines, Invest Urol, 17, 359
- 10.1016/0022-1759(79)90132-7 · DOI
- 10.1210/jcem-57-3-645 · DOI
- Clark JH, 1986, Laboratory Method Manual for Hormone Activity and Molecular Endocrinology, 1
- Wright PW, 1979, Amplification of the proliferative response to alloantigen by a factor present in an extract of syngeneic thymic lymphoid cells: demonstration of optimal conditions and target cell for factor activity, J Immunol, 122, 2435, 10.4049/jimmunol.122.6.2435 · DOI
- Horoszewicz JS, 1983, LNCaP model of human prostatic carcinoma, Cancer Res, 43, 1809
- Kaighn ME, 1979, Establishment and characterization of a human prostatic carcinoma cell line (PC‐3), Invest Urol, 17, 16
- 10.1002/ijc.2910210305 · DOI · Paper page
- 10.1002/pros.2990010113 · DOI
- van Steenbrugge GJ, 1985, Monograph 2, Part A: Therapeutic Principles in Metastatic Prostatic Cancer, 23
- 10.1016/S0022-5347(17)49633-9 · DOI
- 10.1007/BF02623648 · DOI
- 10.1007/BF02623572 · DOI
- 10.1007/BF02619671 · DOI
- 10.1007/BF02618058 · DOI
- 10.1002/jcb.240410205 · DOI
- 10.1021/bi00387a016 · DOI
- 10.1016/0006-291X(86)90455-9 · DOI
- Wilding G, 1988, The role of transforming growth factor α and β in human prostate cancer cell growth. Abstract 957, Endocrinol Proceedings of AACR, 29, 241
- 10.1002/pros.2990130303 · DOI
- 10.1002/pros.2990120108 · DOI
- 10.1002/pros.2990150211 · DOI
- 10.1677/joe.0.1130147 · DOI
- Ramanath Rao B, 1985, Monograph 2, Part A: Therapeutic Principles in Metastatic Prostatic Cancer, 3
- 10.1002/pros.2990070208 · DOI
- 10.1007/BF00256042 · DOI
- 10.1210/endo-121-2-631 · DOI
- 10.1016/S0022-5347(17)37960-0 · DOI
- 10.1002/ijc.2910440525 · DOI
- 10.1016/S0006-291X(05)80067-1 · DOI
- Ilzumi T, 1987, Establishment of a new prostatic carcinoma cell line (TSU‐PR1), J Urol, 137, 1304, 10.1016/S0022-5347(17)44488-0 · DOI
- 10.1016/S0022-5347(17)39797-5 · DOI
- 10.1016/S0022-5347(17)38409-4 · DOI
- 10.1016/0960-0760(90)90441-M · DOI
Cited by
Sorted by citations
The ghosts of HeLa: How cell line misidentification contaminates the scientific literature
Horbach, S. P. J. M., & Halffman, W. (2017) · PLOS ONE · doi:10.1371/journal.pone.0186281 · Cited by 167
Metadata
- Authors
- Loop, S. M., Rozanski, T. A., & Ostenson, R. C.
- Affiliations
- United States Department of Veterans Affairs (US)
- Madigan Army Medical Center (US)
- Corresponding author
- Ostenson, Richard C.
- Venue
- The Prostate
- Publisher
- Wiley
- Published
- 1993-01
- Volume
- 22
- Issue
- 2
- Pages
- 93-108
- ISSN
- 0270-4137 (ISSN-L)
- 1097-0045
- OpenAlex
- W2111183857
- Cited by
- 60
- References
- 0
- Citations by year
- 2024: 1 · 2022: 2 · 2019: 1 · 2018: 1 · 2017: 1 · 2016: 1 · 2015: 2 · 2013: 2 · 2012: 1
- FWCI
- 6.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Prostate (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Reproductive Medicine › Sperm and Testicular Function
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- primary prostate cancer, hormonal regulation of tumor growth, testosterone, prostate-specific antigen, prostatic acid phosphatase, karyotype, chromosome number, xenograft tumor growth, castration, nude mice, cell line establishment
- MeSH terms
- Acid Phosphatase, Animals, Cell Division, Cytosol, Female, Humans, Isoenzymes, Karyotyping, Kinetics, Male, Mice, Nude, Neoplasm Transplantation, Orchiectomy, Ploidies, Prostatic Neoplasms, Receptors, Androgen, Testosterone, Thymidine, Transplantation, Heterologous, Tumor Cells, Cultured, Biomarkers, Prostate-Specific Antigen, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
